Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

Mersana Therapeutics, Inc.

Mersana Therapeutics is focused on discovering and developing antibody-drug conjugates (ADCs) for cancer treatment.

Mersana Therapeutics

Mersana Therapeutics | 12,394 followers on LinkedIn. Our mission is to discover and develop life-changing antibody-drug conjugates (ADCs) for patients fighting cancer. | At Mersana, we have a passion for advancing therapies to make a significant impact in the lives of people living with cancer. 

Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel antibody-drug conjugates (ADCs) and driven by the knowledge that patients are waiting for new treatment options. The company has developed proprietary cytotoxic (Dolasynthen) and immunostimulatory (Immunosynthen) ADC platforms that are generating a pipeline of wholly-owned and partnered product candidates with the potential to treat a range of cancers.

VP, Information, Technology & Risk

Orhan Karsligil

Digital Transformation | Data Strategy | Cloud Strategy | Enterprise Business Applications | Business Analytics|Program Management

Srikanth Chebrolu

SVP, Investor Relations & Corp. Comm.

Jason Fredette

Annette Kranepool

We're happy to be in Houston for #SITC 2024. Looking forward to our presentations focusing on XMT-2056, our Immunosynthen STING agonist #AntibodyDrugConjugate in #HER2 positive tumors (Posters #654 and #1053).

Mersana will be reporting its third quarter financial results next week. Be sure to tune into our conference call for our latest business updates. $MRSN

Excited to be at #WorldADC 2024. Attendees should plan to join our three presentations, including the plenary session with our Chief Science & Technology Officer Timothy Lowinger and discussions with our very own Scott David Collins and Yuanyuan Li .

We are proud to celebrate #GlobalDiversityAwarenessMonth and honor #TeamMersana ’s diverse cultures and perspectives year-round. Our unique backgrounds make us stronger as we continue our innovative work with a focus patients. Caryn Crasnick-Maloney, Baher Daoud , Sandra F. McManus

We are proud to celebrate #GlobalDiversityAwarenessMonth and honor #TeamMersana ’s diverse cultures and perspectives year-round. Our unique backgrounds make us stronger as we continue our innovative work with a focus patients. Kavita Baba Niyanta Kumar Ramani Raghavan

We are proud to celebrate #GlobalDiversityAwarenessMonth and honor #TeamMersana ’s diverse cultures and perspectives year-round. Our unique backgrounds make us stronger as we continue our innovative work with a focus on patients. Rishi Bhattacharjee , Mei J., Sam Kay, CFA

#TeamMersana is happy to be participating in #IGCS2024 . Looking forward to our poster presentation (#1106) sharing clinical data for the combination of carboplatin with an ADC equipped with Mersana's proprietary auristatin payload in ovarian cancer.

Players and fans enjoyed a beautiful Fall afternoon on the field for our #TeamMersana Annual Kickball Classic! Great to see everyone and congrats to the DARgers for their big win against the DrAgonists! #TeamMersana

Today, Mersana recognizes #WorldCancerResearchDay . We continue to work with urgency to develop #AntibodyDrugConjugates that have the potential to better the lives of patients with various cancers. Learn more: https://lnkd.in/eqr6CZR3

Our congratulations go out to Reddy Bollu , Brian DeSchuytner, Orhan Karsligil , Kelly Lancaster, PMP , Ashish Mandelia , Sandra F. McManus and Adi Reske, PhD on their milestone Mersanaversaries! Thanks for your longstanding and ongoing contributions. #TeamMersana

Metric
Company Name	Mersana Therapeutics, Inc.
Symbol	MRSN
MSH ID	COM:MERSANA
Market	STOCKS
Sector	Healthcare
Industry	Biotechnology
Country	US
Stage
Employee Count	123
Website	mersana.com
LinkedIn	mersana-therapeutics
Founders

Metric
Market Cap	239.83M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	36.85M
Revenue (LTM)
Revenue (NTM)
Gross Profit	35.34M
EBITDA	-169.44M
Operating Income	-170.96M
Net Income	-171.67M
EPS	-1.48
Diluted EPS	-1.48
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.96
Operating Profit Margin	-3.60
EBITDA Margin	-4.60
Net Profit Margin	-3.50
Return on Equity	-2.61
Return on Assets	-0.58
Return on Capital Employed	-0.92

COM:MERSANA

Mersana Therapeutics

Last Close

1.98

22/11 21:00

Market Cap

239.83M

Beta: -

Volume Today

587.87K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-2.13
P/B Ratio	8.10
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	15.82
EV Multiple	-1.55

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle	19.14
Cash Conversion Cycle	-627.77
Asset Turnover	0.19

Metric
Operating Cash Flow	-168.88M
Free Cash Flow	-171.05M
Cash Flow to Debt	-3.49
Operating Cash Flow/Sales	-3.77
Free Cash Flow Yield	-0.34

Metric
Cash & Equivalents	174.56M
Accounts Receivable	30M
Inventory
Goodwill
Debt to Capitalization	0.79
Debt to Assets	0.13
Current Ratio	3.68
Quick Ratio	3.51

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.45
R&D to Revenue	4.22
SG&A to Revenue	1.57